# A Study of the Safety and Tolerability of V419 in Healthy Infants at 2,4, 6 and 12 to 14 Months of Age (V419-003)

> **NCT00551915** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 756 (actual)

## Conditions studied

- Bacterial Infections; Virus Diseases

## Interventions

- **BIOLOGICAL:** AR51 (12, 10)
- **BIOLOGICAL:** PR51 (3, 10)
- **BIOLOGICAL:** PR51 (6, 10)
- **BIOLOGICAL:** PENTACEL™
- **BIOLOGICAL:** RECOMBIVAX HB™

## Key facts

- **NCT ID:** NCT00551915
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-05
- **Primary completion:** 2003-01
- **Final completion:** 2003-01
- **Target enrollment:** 756 (ACTUAL)
- **Last updated:** 2015-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00551915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00551915, "A Study of the Safety and Tolerability of V419 in Healthy Infants at 2,4, 6 and 12 to 14 Months of Age (V419-003)". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT00551915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*